Clinical Trials · NCT01471405
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 54
- Start date
- Jan 2012
- Locations
- 18 sites, 6 countries
- Primary endpoint
- Proportion of patients maintained on medical treatment with lanreotide Autogel